¿Ü°ú¿ë ÁöÇ÷Á¦ ½ÃÀå : Á¦Ç° À¯Çü, Á¦Á¦, ¿ëµµ, ÃÖÁ¾ ¿ëµµº° - ¼¼°è ¿¹Ãø(2024-2032³â)
Surgical Hemostats Market, By Product Type (Topical Thrombin-Based, Flowable, Collagen-Based, Oxidized Regenerated Cellulose-Based, Gelatin-Based, & Combination), Formulation (Matrix, Sponge, Powder), Application, End-use -Global Forecast (2024-2032)
»óǰÄÚµå
:
1426971
¸®¼Ä¡»ç
:
Global Market Insights Inc.
¹ßÇàÀÏ
:
2023³â 12¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 214 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¿Ü°ú¿ë ÁöÇ÷Á¦ ½ÃÀå ±Ô¸ð´Â ¼ö¼úÈÄ ÇÕº´ÁõÀ» ÃÖ¼ÒÇÑÀ¸·Î ¾ïÁ¦Çϱâ À§ÇÑ ÇùÁ¶Àû ³ë·Â¿¡ ÀÇÇØ 2024-2032³â CAGR 5.6%·Î È®´ëÇÒ Àü¸ÁÀÔ´Ï´Ù.
ÃÖ±Ù ¼ö³â°£ ¿Ü°ú ÀÇ»çµéÀº ÇÕº´Áõ À§ÇèÀ» ÁÙÀ̰í ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϱâ À§ÇØ ¼ö¼ú Áß ¹× ¼ö¼ú ÈÄ ÃâÇ÷À» Á¦¾îÇÏ´Â È¿°úÀûÀÎ ÁöÇ÷ ¼Ö·ç¼ÇÀ» ¿ì¼±½ÃÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á Àü¹®°¡µéÀÌ È¯ÀÚÀÇ ¾ÈÀü°ú ȸº¹¿¡ Á¡Á¡ ´õ ¸¹Àº °ü½ÉÀ» ±â¿ïÀÌ¸é¼ Ã·´Ü ÁöÇ÷Á¦ÀÇ Ã¤ÅÃÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. È¿´ÉÀ» °³¼±ÇÏ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈÇϱâ À§ÇÑ Çõ½ÅÀûÀÎ ÁöÇ÷ ±â¼úÀÇ Áö¼ÓÀûÀÎ °³¹ßÀÌ Á¦Ç° äÅÿ¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ À¯È¿¼º°ú Àû¿ë¼ºÀ» Çâ»ó½Ã۱â À§ÇÑ Ã·´Ü ¼ÒÀç ¹× Á¦Çü °³¹ß µî ÁöÇ÷Á¦ÀÇ ±â¼ú Çõ½ÅÀÌ ÁøÇàµÇ°í ÀÖ´Â °Íµµ ÁöÇ÷Á¦ »ê¾÷ÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 11¿ù, EthiconÀº ÃâÇ÷ Á¶ÀýÀÌ ¾î·Á¿î »óȲ¿¡¼ ÁöÇ÷À» À¯ÁöÇϱâ À§ÇØ ÀÓ»óÀûÀ¸·Î ÀÎÁõµÈ º¸Á¶ ÁöÇ÷Á¦ÀÎ ETHIZIATMÀÇ ½ÂÀÎÀ» ¹ßÇ¥Çß½À´Ï´Ù.
»ê¾÷Àº Á¦Ç° À¯Çü, Á¦Çü, ¿ëµµ, ÃÖÁ¾ ¿ëµµ, Áö¿ªÀ¸·Î ±¸ºÐµË´Ï´Ù.
Á¦Ç° À¯Çüº°·Î´Â Äݶó°Õ ±â¹Ý ¼ö¼ú¿ë ÁöÇ÷Á¦ ½ÃÀåÀº 2024-2032³â ¿¬Æò±Õ 5.2%ÀÇ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ´Â Äݶó°Õ ±â¹Ý Á¦Ç°ÀÌ ´ÙÀç´Ù´ÉÇϰí ÃâÇ÷À» È¿°úÀûÀ¸·Î ¾ïÁ¦ÇÒ ¼ö ÀÖÀ¸¸ç, ¼±È£µµ°¡ ³ô¾ÆÁ³±â ¶§¹®ÀÔ´Ï´Ù. ¼ö¼ú¿ë ÁöÇ÷Á¦´Â ÁöÇ÷ È¿°ú, »ýü ÀûÇÕ¼º, ´Ù¾çÇÑ ¼ö¼ú ¿ëµµ¿¡¼ »ç¿ë ÆíÀǼºÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ Äݶó°ÕÀÇ Ãµ¿¬ ÁöÇ÷ Ư¼ºÀ¸·Î ÀÎÇØ Á¤Çü¿Ü°ú, ½ÉÇ÷°ü, Ä¡°ú µî ´Ù¾çÇÑ ¼ö¼ú¿¡ ´ëÇÑ »ç¿ëÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Äݶó°Õ ±â¹Ý ÁöÇ÷Á¦ÀÇ ¼º´É°ú Àû¿ë¼ºÀ» Çâ»ó½ÃŰ´Â ±â¼ú ¹ßÀüÀº ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù.
ÃÖÁ¾ ¿ëµµº°·Î´Â ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ºÐ¾ßÀÇ ¼ö¼ú¿ë ÁöÇ÷Á¦´Â 2032³â±îÁö 5.4%ÀÇ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)¿¡¼ÀÇ ÀÇ·á ÀýÂ÷¿¡ ´ëÇÑ È¯ÀÚ ¼±È£µµ°¡ ³ô¾ÆÁö´Â °ÍÀº È¿À²¼º, ºñ¿ë È¿À²¼º, ÃÖ¼Ò Ä§½ÀÀû ½Ã¼ú¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ ¿Ü·¡¿¡¼ ½ÃÇàµÇ´Â ´Ù¾çÇÑ ¿Ü°úÀû ¼ö¼ú¿¡¼ È¿°úÀûÀÎ ÃâÇ÷ Á¶Àý¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ Á¦Ç° ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¼ö¼ú¿ë ÁöÇ÷Á¦ »ê¾÷Àº ¼ö¼ú Áõ°¡, ÀÇ·á ÀÎÇÁ¶ó Áõ°¡, ÷´Ü ÀÇ·á Á¦Ç°¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µîÀ» ¹è°æÀ¸·Î 2024-2032³â »çÀÌ 6%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¸¼ºÁúȯ°ú ¼±ÅÃÀû ¼ö¼úÀÇ ±ÞÁõÀº È¿À²ÀûÀÎ ÁöÇ÷ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á ¹ßÀüÀ» ÃËÁøÇϱâ À§ÇÑ Á¤ºÎÀÇ ±¸»ó°ú ¼ö¼ú ±â¹ýÀÇ Áö¼ÓÀûÀÎ ¹ßÀü, ¼ö¼ú ÈÄ ÇÕº´Áõ ÃÖ¼ÒÈ¿¡ ´ëÇÑ °ÇÑ °ü½É°ú ÇÔ²² Áö¿ª »ê¾÷ÀÇ È®ÀåÀ» °¡¼ÓÈÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¿Ü°ú¿ë ÁöÇ÷Á¦ ¾÷°è ÀλçÀÌÆ®
- ¿¡ÄڽýºÅÛ ºÐ¼®
- ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
- ÃËÁø¿äÀÎ
- ¼¼°èÀÇ ¿Ü°ú¼ö¼ú °Ç¼öÀÇ Áõ°¡
- »ç°í ¹× ¿Ü»óÀÇ Áõ°¡
- ÁöÇ÷ Á¦Ç°ÀÇ ±â¼úÀû Áøº¸ÀÇ Áõ°¡
- ±³Åë»ç°í¿¡ °üÇÑ ÀÇ½Ä Çâ»ó¿¡ ´ëÇÑ Á¤ºÎ ±¸»óÀÇ ±ÞÁõ
- ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
- ÁöÇ÷Á¦¿¡ ÷´Ü ±â¼úÀÌ »ç¿ëµÇ°í ÀÖÀ¸¹Ç·Î ÁöÇ÷Á¦¿¡ °íºñ¿ëÀÌ ÇÊ¿ä
- ¿Ü°ú¼ö¼úÀ» ½ÃÇàÇÏ´Â ¼÷·Ã Àü¹®°¡ÀÇ ºÎÁ·
- ¼ºÀå °¡´É¼º ºÐ¼®
- ±â¼ú Àü¸Á
- °¡°Ý ºÐ¼®
- PorterÀÇ »ê¾÷ ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå °æÀï ±¸µµ
- ¼·Ð
- ±â¾÷ Á¡À¯À² ºÐ¼®
- ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
- °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
- Àü·« Àü¸Á ¸ÅÆ®¸¯½º
Á¦5Àå ¿Ü°ú¿ë ÁöÇ÷Á¦ ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø : Á¦Ç° À¯Çüº°
- ÁÖ¿ä µ¿Çâ : Á¦Ç° À¯Çüº°
- Æ®·Òºó ±â¹Ý ±¹¼Ò ÁöÇ÷Á¦
- À¯µ¿¼º ÁöÇ÷Á¦
- Äݶó°Õ ÁöÇ÷Á¦
- »êÈ Àç»ý ¼¿·ê·Î¿À½º°è ÁöÇ÷Á¦
- Á©¶óƾ ÁöÇ÷Á¦
- ÄÞºñ³×ÀÌ¼Ç ÁöÇ÷Á¦
- ±âŸ Á¦Ç° À¯Çü
Á¦6Àå ¿Ü°ú¿ë ÁöÇ÷Á¦ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Á¦º°
- ÁÖ¿ä µ¿Çâ : Á¦Çüº°
- ¸ÅÆ®¸¯½º & °Ö ÁöÇ÷Á¦
- ½ºÆÝÁö ÁöÇ÷Á¦
- ½ÃÆ®¡¤ÆÐµå ÁöÇ÷Á¦
- ºÐ¸» ÁöÇ÷Á¦
Á¦7Àå ¿Ü°ú¿ë ÁöÇ÷Á¦ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿ëµµº°
- ÁÖ¿ä µ¿Çâ : ¿ëµµº°
- ÀÏ¹Ý ¿Ü°ú
- ½ÉÀåÇ÷°ü ¿Ü°ú
- Á¤Çü¿Ü°ú
- ºÎÀΰú ¿Ü°ú
- ½Å°æ¿Ü°ú
- Àç°Ç ¿Ü°ú
- ±âŸ ¿ëµµ
Á¦8Àå ¿Ü°ú¿ë ÁöÇ÷Á¦ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÃÖÁ¾ ¿ëµµº°
- ÁÖ¿ä µ¿Çâ : ÃÖÁ¾»ç¿ëÀÚº°
- Áø·á¼Ò
- º´¿ø
- ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
- ±âŸ ÃÖÁ¾»ç¿ëÀÚ
Á¦9Àå ¿Ü°ú¿ë ÁöÇ÷Á¦ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
- ÁÖ¿ä µ¿Çâ : Áö¿ªº°
- ºÏ¹Ì
- À¯·´
- µ¶ÀÏ
- ¿µ±¹
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ÀÌÅ»¸®¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- ºê¶óÁú
- ¸ß½ÃÄÚ
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦10Àå ±â¾÷ °³¿ä
- Becton, Dickinson and Company
- Medtronic plc
- Teleflex Corporation
- Baxter International Inc.
- B. Braun Melsungen AG
- Pfizer, Inc.
- Ethicon, Inc.(Johnson & Johnson)
- Stryker Corporation
- CuraMedical BV
- Gelita Medical GmbH
- Integra LifeSciences
- Marine Polymer Technologies, Inc.
- Hemostasis LLC
KSA
¿µ¹® ¸ñÂ÷
Surgical Hemostats Market size is poised to expand at 5.6% CAGR from 2024 to 2032 driven by the concerted efforts to minimize postoperative complications.
Of late, surgeons are prioritizing effective hemostatic solutions to control bleeding during and after surgical procedures for reducing the risk of complications and improving patient outcomes. Healthcare professionals are increasingly emphasizing patient safety and recovery, surging the adoption of advanced hemostatic agents. The continuous development of innovative hemostatic technologies, aimed at enhancing efficacy and minimizing adverse effects will fuel the product adoption. Furthermore, the ongoing innovations in hemostatic agents, including the development of advanced materials and formulations to improve efficacy and applicability will contribute to the industry growth. For instance, in November 2023, Ethicon announced the approval of ETHIZIATM, a clinically certified supplementary hemostat solution to maintain hemostasis in circumstances of difficult-to-control bleeding.
The industry is segmented into product type, formulation, application, end-use, and region.
Based on product type, the collagen-based surgical hemostats market is projected to witness 5.2% CAGR between 2024 and 2032. This is owing to the increasing preference for collagen-based products for their versatility and ability to control bleeding effectively. Surgical hemostats provide hemostatic efficacy, biocompatibility, and ease of use in various surgical applications. Additionally, the natural hemostatic properties of collagen are surging its use for diverse surgeries, including orthopedic, cardiovascular, and dental procedures. Furthermore, technological advancements to enhance the performance and applicability of collagen-based hemostats will propel the segment growth.
In terms of end-use, the surgical hemostats industry from the ambulatory surgical centers segment is expected to record 5.4% growth rate through 2032. The growing patient preference for medical treatments at ambulatory surgical centers (ASCs) can be attributed to their efficiency, cost-effectiveness, and minimally invasive procedures. The rising need for effective bleeding control in diverse surgical interventions performed in outpatient settings is also fueling the product demand.
Asia Pacific surgical hemostats industry is set to exhibit 6% growth rate during 2024-2032 attributed to the rising surgical procedures, increasing healthcare infrastructure, and the growing awareness about advanced medical products. The surging prevalence of chronic diseases and elective surgeries is contributing to the higher demand for efficient hemostatic solutions. Moreover, government initiatives for promoting healthcare development coupled with the ongoing advancements in surgical techniques and the strong focus on minimizing postoperative complications will accelerate the regional industry expansion.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Base estimates & working
- 1.3 Data collection
- 1.4 Forecast parameters
- 1.5 Data validation
- 1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
- 1.6.2.1 Paid sources
- 1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
- 2.1 Surgical hemostats industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Product type trends
- 2.1.4 Formulation trends
- 2.1.5 Application trends
- 2.1.6 End-use trends
Chapter 3 Surgical Hemostats Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Growing number of surgical procedures globally
- 3.2.1.2 Increasing incidence of accidents and trauma cases
- 3.2.1.3 Rising technological advancements in hemostasis products
- 3.2.1.4 Surge in government initiatives towards awareness regarding road traffic accidents
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High expense needed for hemostasis products due to the usage of advanced technology for hemostats
- 3.2.2.2 Lack of skilled professionals for carrying out surgical procedures
- 3.3 Growth potential analysis
- 3.3.1 By product type
- 3.3.2 By formulation
- 3.3.3 By application
- 3.3.4 By end-use
- 3.4 Technology landscape
- 3.5 Pricing analysis
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive analysis of major market players, 2023
- 4.4 Competitive positioning matrix, 2023
- 4.5 Strategic outlook matrix, 2023
Chapter 5 Surgical Hemostats Market Size and Forecast, By Product Type, 2018-2032 (USD Million)
- 5.1 Key trends, by product type
- 5.2 Topical thrombin-based hemostats
- 5.3 Flowable hemostats
- 5.4 Collagen-based hemostats
- 5.5 Oxidized regenerated cellulose-based hemostats
- 5.6 Gelatin-based hemostats
- 5.7 Combination hemostats
- 5.8 Other product types
Chapter 6 Surgical Hemostats Market Size and Forecast, By Formulation, 2018-2032 (USD Million)
- 6.1 Key trends, by formulation
- 6.2 Matrix & gel hemostats
- 6.3 Sponge hemostats
- 6.4 Sheet & pad hemostats
- 6.5 Powder hemostats
Chapter 7 Surgical Hemostats Market Size and Forecast, By Application, 2018-2032 (USD Million)
- 7.1 Key trends, by application
- 7.2 General surgery
- 7.3 Cardiovascular surgery
- 7.4 Orthopedic surgery
- 7.5 Gynecological surgery
- 7.6 Neurosurgery
- 7.7 Reconstructive surgery
- 7.8 Other applications
Chapter 8 Surgical Hemostats Market Size and Forecast, By End-use, 2018-2032 (USD Million)
- 8.1 Key trends, by end-use
- 8.2 Clinics
- 8.3 Hospitals
- 8.4 Ambulatory surgical centers
- 8.5 Other end-users
Chapter 9 Surgical Hemostats Market Size and Forecast, By Region, 2018-2032 (USD Million)
- 9.1 Key trends, by region
- 9.2 North America
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
- 9.6 Middle East & Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
- 10.1 Becton, Dickinson and Company
- 10.2 Medtronic plc
- 10.3 Teleflex Corporation
- 10.4 Baxter International Inc.
- 10.5 B. Braun Melsungen AG
- 10.6 Pfizer, Inc.
- 10.7 Ethicon, Inc. (Johnson & Johnson)
- 10.8 Stryker Corporation
- 10.9 CuraMedical BV
- 10.10 Gelita Medical GmbH
- 10.11 Integra LifeSciences
- 10.12 Marine Polymer Technologies, Inc.
- 10.13 Hemostasis LLC
°ü·ÃÀÚ·á